Introducing Factor XI: Isis Says New Anticoagulant Has Less Bleeding And Antidote
This article was originally published in Pharmaceutical Approvals Monthly
Candidate has potential across the board, but most likely will first be developed in two targeted indications where available anticoagulants are not typically an option due to bleeding risk.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.